Disclaimer: The presented model to determine the benefit of endovascular treatment for acute ischemic stroke is the result of carefully conducted research. This decision tool has been developed based on data of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN). External validation and update of the model was performed using individual patient data of six trials within the HERMES collaboration (ESCAPE, REVASCAT, SWIFT-PRIME, EXTEND-IA, and PISTE) and the observational MR CLEAN Registry.
Before you use the app, make sure that you read this background information, which will help you to interpret its output: the statistical analysis plan (Towards personalised intra-arterial treatment of patients with acute ischaemic stroke: a study protocol for development and validation of a clinical decision aid; BMJ Open 2017 ; doi: 10.1136/bmjopen-2016-013699), the main paper (Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool; BMJ 2017 ), and the external validation and update (Prediction of outcome and endovascular treatment benefit; validation and update of the MR PREDICTS decision tool; Stroke 2021)
As a model can never replace clinical judgement, it can only be used as a decision-support tool. This decision tool should be used exclusively by health care professionals as a complementary tool to estimate treatment benefit of intra-arterial treatment in patients diagnosed with acute ischemic stroke caused by large vessel occlusion. Any responsibility for using this model and its results will rest solely by the health care professional using the model. Using it you should understand and agree that this site is not responsible or liable for any claim, loss, or damage resulting from its use. While we try to keep the information on the site as accurate as possible, we disclaim any warranty concerning its accuracy, timeliness, and completeness, and any other warranty, express or implied, including warranties of merchantability or fitness for a particular purpose.
Go to the MR PREDICTS decision tool
Please click here to use the original decision tool which was published in the main paper (BMJ 2017).